Armistice Capital, LLC Increases Stake in Ekso Bionics Holdings, Inc. to 4.99%

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A (Amendment No. 4) regarding their holdings in Ekso Bionics Holdings, Inc. (EKSO). The filing discloses that the reporting persons beneficially own 187,151 shares of common stock, representing a 4.99% ownership stake in the company. This position is held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to have shared voting and dispositive power over these shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. Notably, this amendment reflects an increase in holdings compared to the previous reported value of zero, positioning the reporting persons just below the 5% threshold. The event necessitating this filing occurred on March 31, 2026.